Anaerobic Bacteria as Therapeutic Agents for Metastatic

厌氧细菌作为转移性治疗剂

基本信息

  • 批准号:
    7025161
  • 负责人:
  • 金额:
    $ 16.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-02-01 至 2008-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): As they grow in volume many tumors, including pancreatic and colon cancers, construct poorly vascularized and oxygen-deficient (hypoxic) areas that restrict the access by therapeutic agents and limit the efficacy of currently used anti-cancer modalities. However, the presence of hypoxia also offers the potential for anaerobic bacterial colonization that can lead to tumor destruction. One such anerobic bacterium is Clostridium perfringens (Cp), which contains a major toxin gene that encodes phospholipase C (plc). A plc-deleted strain of Cp (Cp/plc-) has been constructed in our laboratory and shown, after intravenous administration, to colonize and induce massive necrosis in solid tumors in mice. Unfortunately Cp/plc- retains some tolerance to oxygen that enables it to grow in normal tissues at a much reduced rate, and tumor-bearing mice treated with Cp/plc- at the effective doses also exhibited systemic toxicity. We hypothesize that Cp/plc- can be genetically modified to reduce substantially its oxygen tolerance, thereby creating sub-strains that will lead to tumor destruction without toxicity to normal tissues. We propose to delete the superoxide dismutase (sod) gene in a luciferase-expressing strain of Cp/plc-/LUC+ (Cp/plc-/sod-/LUC+). Immune- competent mice with pre-established syngeneic colorectal and pancreatic cancers in the liver will be treated by intravenous administration of Cp/plc-/sod-. Dose response curve and long-term survival at the maximal tolerated dose will be determined. Bacterial biodistribution and intratumoral growth will be determined as a function of time by repeated non-invasive whole-body imaging using luciferrin. Tumor responses in the treated animals will be evaluated by histological examination. Toxicity endpoints will include CBC, blood chemistries, serum proinflammatory cytokine levels and history of major organs. If necessary, additional oxygen tolerance genes can be deleted from Cp/plc-/sod- to further reduce toxicity. We hypothesize that these oxygen-intolerant mutant bacterial sub-strains can be safely applied in tumor-bearing animals, which will selectively localize to, germinate and grow in, and destroy tumors in hypoxic regions. Application of anaerobic bacterial-based vectors is a promising strategy for the development of an effective therapeutic agent that can be administered systemically to treat disseminated solid tumors with hypoxia, and may lead to clinical translational studies in patients with metastatic colorectal and/or pancreatic cancers in the future.
描述(由申请人提供):随着许多肿瘤(包括胰腺癌和结肠癌)的体积增长,它们会形成血管化不良和缺氧(缺氧)区域,这限制了治疗剂的进入,并限制了目前使用的抗癌方式的疗效。然而,缺氧的存在也提供了可能导致肿瘤破坏的厌氧菌定植的可能性。一种这样的厌氧细菌是产气荚膜梭菌(Cp),其含有编码磷脂酶C(plc)的主要毒素基因。在我们的实验室中构建了Cp的plc缺失菌株(Cp/plc-),并显示静脉给药后,在小鼠实体瘤中定殖并诱导大量坏死。不幸的是,Cp/plc-保留了一定的氧耐受性,使其能够以大大降低的速率在正常组织中生长,并且用有效剂量的Cp/plc-治疗的荷瘤小鼠也表现出全身毒性。我们假设Cp/plc-可以被遗传修饰以显著降低其氧耐受性,从而产生将导致肿瘤破坏而对正常组织没有毒性的亚株。我们建议删除的超氧化物歧化酶(sod)基因的表达菌株Cp/plc-/LUC+(Cp/plc-/sod-/LUC+)。将通过静脉内施用Cp/plc-/sod-来治疗在肝脏中具有预先建立的同基因结肠直肠癌和胰腺癌的免疫活性小鼠。将确定最大耐受剂量下的剂量反应曲线和长期生存期。细菌生物分布和肿瘤内生长将通过使用白藜芦醇的重复非侵入性全身成像来确定为时间的函数。将通过组织学检查评价给药动物的肿瘤缓解。毒性终点将包括CBC、血液化学、血清促炎细胞因子水平和主要器官病史。如有必要,可以从Cp/plc-/sod-中删除额外的耐氧基因,以进一步降低毒性。我们假设这些不耐氧突变细菌亚株可以安全地应用于荷瘤动物,其将选择性地定位于缺氧区域,在缺氧区域萌发和生长并破坏肿瘤。基于厌氧菌的载体的应用是一种有前途的策略,用于开发一种有效的治疗剂,该治疗剂可以全身给药以治疗伴有缺氧的播散性实体瘤,并且可能导致未来在转移性结直肠癌和/或胰腺癌患者中的临床转化研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Savio L Woo其他文献

Savio L Woo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Savio L Woo', 18)}}的其他基金

Anaerobic Bacteria as Oncopathic Agents for Pancreatic Cancer
厌氧细菌作为胰腺癌的致癌剂
  • 批准号:
    7651591
  • 财政年份:
    2009
  • 资助金额:
    $ 16.1万
  • 项目类别:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
溶瘤 rVSV-F 病毒疗法治疗 HCC 的 I 期临床转化试验
  • 批准号:
    7077291
  • 财政年份:
    2006
  • 资助金额:
    $ 16.1万
  • 项目类别:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
溶瘤 rVSV-F 病毒疗法治疗 HCC 的 I 期临床转化试验
  • 批准号:
    7667824
  • 财政年份:
    2006
  • 资助金额:
    $ 16.1万
  • 项目类别:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
溶瘤 rVSV-F 病毒疗法治疗 HCC 的 I 期临床转化试验
  • 批准号:
    7476525
  • 财政年份:
    2006
  • 资助金额:
    $ 16.1万
  • 项目类别:
Anaerobic Bacteria as Therapeutic Agents for Metastatic Cancer
厌氧细菌作为转移性癌症的治疗剂
  • 批准号:
    7229908
  • 财政年份:
    2006
  • 资助金额:
    $ 16.1万
  • 项目类别:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
溶瘤 rVSV-F 病毒疗法治疗 HCC 的 I 期临床转化试验
  • 批准号:
    7929907
  • 财政年份:
    2006
  • 资助金额:
    $ 16.1万
  • 项目类别:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
溶瘤 rVSV-F 病毒疗法治疗 HCC 的 I 期临床转化试验
  • 批准号:
    7276134
  • 财政年份:
    2006
  • 资助金额:
    $ 16.1万
  • 项目类别:
GROWTH, DIFFERENTIATION AND GENETIC ALTERATION OF HUMAN ES CELLS
人类 ES 细胞的生长、分化和遗传改变
  • 批准号:
    7092813
  • 财政年份:
    2005
  • 资助金额:
    $ 16.1万
  • 项目类别:
Genetic Reconstitution for Phenylketonuria
苯丙酮尿症的基因重建
  • 批准号:
    6680669
  • 财政年份:
    2003
  • 资助金额:
    $ 16.1万
  • 项目类别:
Genetic Reconstitution for Phenylketonuria
苯丙酮尿症的基因重建
  • 批准号:
    6894830
  • 财政年份:
    2003
  • 资助金额:
    $ 16.1万
  • 项目类别:

相似海外基金

Identification and isolation of anaerobic bacteria that degrade bacterial cell wall
降解细菌细胞壁的厌氧菌的鉴定与分离
  • 批准号:
    22H02487
  • 财政年份:
    2022
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Enzymology of cofactor and amino acid metabolism in anaerobic bacteria
厌氧菌辅助因子和氨基酸代谢的酶学
  • 批准号:
    RGPIN-2022-03200
  • 财政年份:
    2022
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Discovery Grants Program - Individual
High-throughput isolation of anaerobic bacteria
厌氧菌的高通量分离
  • 批准号:
    572711-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 16.1万
  • 项目类别:
    University Undergraduate Student Research Awards
Elucidating the mechanisms of O2-sensitivity of anaerobic bacteria Bifidobacterium.
阐明厌氧菌双歧杆菌的 O2 敏感性机制。
  • 批准号:
    22K07058
  • 财政年份:
    2022
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Automatic and accurate identification of aerobic bacteria, anaerobic bacteria, yeasts, and fungi in clinical samples derived from animals and from feed for pets
自动、准确地鉴定来自动物和宠物饲料的临床样品中的需氧细菌、厌氧细菌、酵母菌和真菌
  • 批准号:
    10440741
  • 财政年份:
    2021
  • 资助金额:
    $ 16.1万
  • 项目类别:
Regulation of virulence in fungi under coculture condition with anaerobic bacteria
厌氧菌共培养条件下真菌毒力的调节
  • 批准号:
    21K07009
  • 财政年份:
    2021
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Polymicrobial interactions between commensal obligate anaerobic bacteria and cystic fibrosis pathogen P. aeruginosa
共生专性厌氧菌与囊性纤维化病原体铜绿假单胞菌之间的多种微生物相互作用
  • 批准号:
    10275319
  • 财政年份:
    2021
  • 资助金额:
    $ 16.1万
  • 项目类别:
Platform for the automated isolation and characterization of anaerobic bacteria
厌氧菌自动分离和表征平台
  • 批准号:
    445552570
  • 财政年份:
    2020
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Major Research Instrumentation
Development of therapy for triple negative breast cancer using anaerobic bacteria
利用厌氧菌开发三阴性乳腺癌疗法
  • 批准号:
    19K16452
  • 财政年份:
    2019
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of gene engineering method for anaerobic bacteria for efficient bio-hydrogen production
开发厌氧菌高效生物制氢的基因工程方法
  • 批准号:
    18K11708
  • 财政年份:
    2018
  • 资助金额:
    $ 16.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了